Analysts Set Kalaris Therapeutics Inc. (NASDAQ:KLRS) Target Price at $18.75

Posted by Stanley Muller on Aug 11th, 2026

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $18.75.

Several brokerages have recently weighed in on KLRS. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday, May 13th. TD Cowen started coverage on Kalaris Therapeutics in a research report on Monday, June 15th. They issued a “buy” rating on the stock. Morgan Stanley initiated coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 target price on the stock. Weiss Ratings downgraded Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, June 14th.

Get Our Latest Stock Analysis on KLRS

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $3.94 on Thursday. The business’s 50 day moving average is $4.28 and its two-hundred day moving average is $6.27. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $11.88. The stock has a market capitalization of $93.73 million, a P/E ratio of -1.83 and a beta of 0.20.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. As a group, equities research analysts anticipate that Kalaris Therapeutics will post -2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju purchased 244,300 shares of Kalaris Therapeutics stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $4.83 per share, with a total value of $1,179,969.00. Following the purchase, the director directly owned 2,224,147 shares of the company’s stock, valued at approximately $10,742,630.01. This represents a 12.34% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 68.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. RTW Investments LP bought a new stake in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $10,972,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter valued at approximately $5,908,000. Alyeska Investment Group L.P. bought a new position in Kalaris Therapeutics in the fourth quarter worth approximately $3,402,000. Ikarian Capital LLC bought a new position in Kalaris Therapeutics in the fourth quarter worth approximately $3,038,000. Finally, Woodline Partners LP purchased a new position in Kalaris Therapeutics during the 3rd quarter worth $1,394,000. 66.05% of the stock is currently owned by institutional investors.

Kalaris Therapeutics Company Profile

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.